To learn more about ALREX, visit
our website at www.bausch.com
|
|
Indication
ALREX Ophthalmic Suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
Important Safety Information
| • |
As with other ophthalmic corticosteroids, ALREX is contraindicated in most viral diseases of the cornea and conjunctiva, and in mycobacterial and fungal diseases of the eye. Prolonged use of corticosteroids may result in secondary glaucoma, cataract formation, and secondary ocular infections following suppression of the host immune response and/or perforation of the globe |
| • |
The renewal of the medication order beyond 14 days should be made by a physician only after examination with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If this product is used for 10 days or longer, intraocular pressure should be monitored |
| • |
The most common adverse events in patients treated with ALREX were abnormal vision, blurring, burning, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, and photophobia. Non-ocular adverse reactions include headache, rhinitis, and pharyngitis |
Please view the full prescribing information for Alrex.
References:
1. ALREX® Prescribing Information, August 2008, Bausch & Lomb Incorporated. 2. Slonim CB, Boone R. The ocular allergic response: a pharmacotherapeutic review. Formulary. 2004;39:213-222. 3. PatadayTM Prescribing Information, Alcon, Inc. 4. Elestat® Prescribing Information, August 2008, Allergan, Inc. 5. Zaditor® Prescribing Information, October 2002, Novartis Pharmaceuticals Corporation. 6. Optivar® Prescrbing Information, July 2008, Meda Pharmaceuticals Inc. 7. Nichols KK, Morris S, Weibel KA. Get the reaction you want. Optom Manage. 2006.
BNET Web site. http://findarticles.com/p/articles/mi_qa3921/is_200604/ai_n17174436. Published April 2009. Accessed July 13, 2009. 8. Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol. 1998;102(2):251-255. 9. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology. 1999;106(2):362-369.
ALREX is a registered trademark of Bausch & Lomb Incorporated.
Pataday is a trademark of Alcon, Inc.
Elestat is a registered trademark of Allergan, Inc.
Zaditor is a registered trademark of Novartis Pharmaceuticals Corporation.
Optivar is a registered trademark of Meda Pharmaceuticals Inc.
© 2010 Bausch & Lomb Incorporated. PHXXXX 2/10 |
|
